Clinical trials: Positron Emission Tomography
Normal Physiology
Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI
Background: Dopamine (DA) is a chemical signal in the brain linked to learning, memory, and habits. Stimulant drugs like methylphenidate can increase DA in the brain. Researchers want to measure DA with and without this drug.
- Trial name
- NCT03326245
- Testing
- Methylphenidate Pill, Intravenous methylphenidate
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Renal Cell Carcinoma, Kidney Cancer
Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.
- Trial name
- NCT00606632
- Testing
- 124-Iodine-cG250 (124I-cG250), CT
- Where
- 14 sites in United States
- Volunteers
- 226 people
- Sponsor
- Heidelberg Pharma AG
Metastatic Neuroblastoma
A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma
This study aims to show that 3-dimensional PET/CT imaging with a new novel PET tracer (called [124I]mIBG) can detect as many or more sites of neuroblastoma (a type of childhood cancer) compared to the recommended 1-dimensional…
- Trial name
- NCT02043899
- Testing
- [124I]meta-Iodobenzylguanidine
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Cancer Research UK
Hodgkin's Lymphoma
Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma
The primary objective of the study is to determine the progression-free survival [PFS] at 36 months for patients with Hodgkin lymphoma who achieve a complete metabolic response as demonstrated by a negative fluorodeoxyglucose…
- Trial name
- NCT00901303
- Testing
- ABVD chemotherapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Weill Medical College of Cornell University
Healthy
PET Study of Repeated ASN51 in Healthy Volunteers
This is a phase 1, open-label, dose escalation, positron emission tomography (PET) study to investigate the brain occupancy of O-GlcNAcase, and the pharmacodynamics (PD) response in peripheral blood mononuclear cells (PBMCs)…
- Trial name
- NCT05725005
- Testing
- ASN51
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Asceneuron S.A.
Transthyretin Amyloidosis
Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR
This was a single center, prospective cohort study that is evaluating the ability of 124I-evuzamitide PET scanning to detect potential therapeutic changes in subjects under treatment for ATTR after one year had elapsed since…
- Trial name
- NCT05635045
- Testing
- I 124-Evuzamitide
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Columbia University
Healthy
A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.
The main objective of this trial is to investigate the effect of multiple oral dosing of high dose BI 1467335 over 28 days and multiple oral dosing of low dose BI 1467335 over 42 days on MAO-B occupancy in the brain compared to…
- Trial name
- NCT03927209
- Testing
- BI 1467335
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Carotid Artery Disease, Carotid Stenosis
TRACER RGD-K5 Carotid Plaque Imaging Study
The purpose of this study is to investigate the ability of the compound[F-18]RGD-K5, when used as a tracer during PET (positron emission tomography) imaging, to detect regions of unstable atherosclerotic plaque in the carotid…
- Trial name
- TRACER (NCT01968226)
- Testing
- [F-18] RDG-K5
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The Cleveland Clinic
Nervous System Disease
PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome
Background: McCune-Albright Syndrome (MAS) is a disorder that affects the bones, skin, and some hormone-producing tissues. It is associated with a mutation in a gene. This gene affects enzymes in the brain and body.
- Trial name
- NCT02743377
- Testing
- Brain PET Imaging with 11C Rolipram, Whole Body PET Baseline with 11C Rolipram, Whole Body PET Blocked with Roflumilast
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Mental Health (NIMH)
Prostate Cancers
FACBC Positron Emission Tomography/Computed Tomography(PET/CT) Used in the Diagnosis of Primary Prostate Cancer
The purpose of this research project is to test if a compound (chemical substance) has a natural tendency to go to prostate cancer. This compound has a small amount of radioactivity attached to it and is called a radiotracer.
- Trial name
- NCT00917865
- Testing
- anti [18F]FACBC
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- David M. Schuster, MD
Healthy Volunteers, Diabetes Mellitus, Type 1
Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass
Type 1 diabetes mellitus (T1DM) develops when there is impaired insulin production due to loss of insulin producing cells (beta cells).
- Trial name
- NCT02236754
- Testing
- 18 F-FP-DTBZ, PET Scanning
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Columbia University
Indication for a PET CT Exam
Development of an Integrated Positron Emission Tomography/Magnetic Resonance (PET/MR) System, Accessories and Components
The PET/MR device components and accessories are under development in order to optimize, validate and improve the design including improving the quality of images.
- Trial name
- NCT01992354
- Testing
- PET MR Device
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GE Healthcare
Cystic Fibrosis
FDG-PET Imaging in Young Cystic Fibrosis Patients
The purpose of this research is to determine how a person's lungs will uptake [18F]fluorodeoxyglucose (FDG), as measured with positron emission tomography (PET) scanning in young cystic fibrosis (CF) patients.
- Trial name
- NCT00846053
- Testing
- FDG-PET
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Dementia
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand
Background: Aging-related progressive neurological disorders include frontotemporal dementia, Lou Gehrig s disease, and Alzheimer s disease. Little is known about what causes these disorders. Brain inflammation may be involved.
- Trial name
- NCT03958630
- Testing
- 11C-ER176, 11C-PIB, Positron Emission Tomography (PET) Scan
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Metastatic Prostate Cancer
Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer
This research is being done to see if an investigational radioactive drug called 18F-DCFBC can help us find cancer that has spread (metastatic disease) from its original site in people who have cancer in their prostate to other…
- Trial name
- NCT01815515
- Testing
- 18F-DCFBC
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment
This prospective study will enroll up to 330 men with PSA-persistent or PSA-recurrent prostate cancer after curative-intent primary therapy and negative or equivocal findings on standard-of-care imaging.
- Trial name
- LOCATE (NCT02680041)
- Testing
- 18F-fluciclovine PET CT
- Where
- 17 sites in United States
- Volunteers
- 221 people
- Sponsor
- Blue Earth Diagnostics
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Trial name
- NCT03822845
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michael Graham PhD, MD
Metastatic Breast Cancer to the Brain
18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain
The purpose of this study is to compare two different imaging methods to examine the response of brain metastases to WBRT. These two imaging methods will take pictures of the brain using : 1) a positron emission tomography (PET)…
- Trial name
- NCT01621906
- Testing
- 18F-FLT-PET Imaging
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Obesity, Heart Failure
Sex and Obesity: Effects on Heart Failure Study
Sex has a major impact on myocardial metabolism and blood flow. In those without heart failure men's hearts tend to use proportionally more glucose and women's hearts use more fat and have higher blood flow.
- Trial name
- NCT00776035
- Testing
- PET (Positron Emission Tomography), Echocardiogram, ^15O-water
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Washington University School of Medicine
Lung Cancer
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET), (done before, during, and after chemotherapy) may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00227539
- Testing
- cisplatin, pemetrexed disodium, adjuvant therapy
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Washington